Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01445080 · ClinicalTrials.gov registry record · Phase 1
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
A Phase 1 study of Juvenile Myelomonocytic Leukemia and Recurrent Childhood Acute Lymphoblastic Leukemia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
- 20
- Study locations
NCT01445080 is a Phase 1 study of Juvenile Myelomonocytic Leukemia and Recurrent Childhood Acute Lymphoblastic Leukemia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 70 participants, below the 132-participant average among 11 other Juvenile Myelomonocytic Leukemia trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT01445080, a Phase 1 study of Juvenile Myelomonocytic Leukemia and Recurrent Childhood Acute Lymphoblastic Leukemia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Sorafenib Tosylate
Study Locations (20)
California
- Children's Hospital of Orange County - Orange
- Lucile Packard Children's Hospital Stanford University - Palo Alto
Indiana
- Indiana University/Melvin and Bren Simon Cancer Center - Indianapolis
- Riley Hospital for Children - Indianapolis
New York
- Columbia University/Herbert Irving Cancer Center - New York
- State University of New York Upstate Medical University - Syracuse
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Children's Hospital of Pittsburgh of UPMC - Pittsburgh
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
District of Columbia
- Children's National Medical Center - Washington D.C.
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2006-05-30 |
| Est. Completion | 2012-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01445080
The ClinicalTrials.gov registry entry for NCT01445080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 132-participant average among 11 other Juvenile Myelomonocytic Leukemia trials with a reported enrollment target (47% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Juvenile Myelomonocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01445080 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, Indiana, New York.
Frequently Asked Questions
What is clinical trial NCT01445080 about?
NCT01445080 is a clinical study titled "Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia". This phase I/II trial is studying the side effects and best dose of sorafenib in treating young patients with relapsed or refractory solid tumors or leukemia. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer...
What is the current status of trial NCT01445080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2006-05-30. Estimated completion is 2012-12-10.
What conditions does trial NCT01445080 study?
This clinical trial studies the following conditions: Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Childhood Acute Myeloid Leukemia, Blastic Phase.
What interventions are being tested in trial NCT01445080?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT01445080?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01445080 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Juvenile Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
RECRUITING · NA
Explore more on PlainTrial
Juvenile Myelomonocytic Leukemia
All registered trials for this condition
Recurrent Childhood Acute Lymphoblastic Leukemia
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.